The Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise / 대한내과학회지
Korean Journal of Medicine
;
: 246-251, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-759939
ABSTRACT
“Precision” trials, using reasonably integrated biomarker targets and molecularly selective anticancer agents, have become a major concern for both patients and their physicians. As next-generation sequencing, which is a parallel analysis method, becomes quicker, easier, and more accurate, precision medicine-based approaches are becoming more generalized in determining treatments for cancer patients. However, it is not applicable to all cancer patients because of current high prices, limited reimbursement coverage, low prevalence of driver genetic mutations, and lack of treatable drugs. To solve these problems, the Republic of Korea has been operating the Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise since its establishment in June 2017. The aim of the project was to conduct large-scale genomic analyses, appropriate matching targeted clinical trials, and data management, which incorporates genomic and clinical information. In this review, we introduce the goals and composition of this project and describe the progress of the project to date.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prevalência
/
Diagnóstico
/
Medicina de Precisão
/
República da Coreia
/
Terapia de Alvo Molecular
/
Sequenciamento de Nucleotídeos em Larga Escala
/
Métodos
/
Antineoplásicos
Tipo de estudo:
Estudo diagnóstico
/
Estudo de prevalência
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS